ClinicalTrials.gg
CompletedNCT02723071Updated Mar 30, 2016

A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)

A Phase 1/2 interventional study of Ocrelizumab in Non-Hodgkin's Lymphoma, sponsored by Hoffmann-La Roche. Completed at 23 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-30.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
48
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche — 1 open to participants now, 6 under way, 1 of them phase 3. Lymphoma, Non-Hodgkin · Hoffmann-La Roche.

Enrollment
36th of 49
48 · median 121
Started
2005
with 2 others
Phase 1/2
13 of 54
none open now
Registered
40th of 54
by date

Among the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, this one is the 36th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2005, is one of 13 in phase 1/2, and was the 40th registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Lymphoma, Non-Hodgkin by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.

03

Conditions studied

  • Non-Hodgkin's Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Follicular NHL
  • Documented history of response, or stable disease more than 6 months in duration, to a rituximab-containing regimen that was the last treatment before enrollment in the study
  • No evidence of or C

Exclusion criteria

Exclusion Criteria:

  • Prior monoclonal antibody therapy other than rituximab, anti-cancer vaccine, or radioimmunotherapy for cancer
  • History of severe allergic or anaphylactic reaction to humanized or murine monoclonal antibodies, or known sensitivity or allergy to murine products
  • Major nondiagnostic surgery within 4 weeks of Screening
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Cohort A: Ocrelizumab 200 mg/m^2

    Participants will receive a total of 8 infusions of ocrelizumab 200 milligram per square meter (mg/m\^2) given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

    Drug: Ocrelizumab

  • Experimental
    Cohort B: Ocrelizumab 375 mg/m^2

    Participants will receive a total of 8 infusions of ocrelizumab 375 mg/m\^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

    Drug: Ocrelizumab

  • Experimental
    Cohort C: Ocrelizumab 375/750 mg/m^2

    Participants will receive first infusion of ocrelizumab 375 mg/m\^2 followed by 7 infusions of 750 mg/m\^2 given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

    Drug: Ocrelizumab

Interventions

  • Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.

    Also known as: RO4964913

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-limiting Toxicity (DLT)

    Time frame: first cycle (3-week cycle) of Cohort A, Cohort B, and Cohort C

Secondary outcomes

  1. Progression-free Survival According to the International Workshop to Standardize Response Criteria for NHL

    Time frame: Day 1, after 4 and 8 cycles of therapy (12 and 24 weeks after study entry) until disease progression/relapse, or death, whichever occurred first (overall up to approximately 2.75 years)

  2. Event-free Survival According to the International Workshop to Standardize Response Criteria for NHL

    Time frame: Day 1, after 4 and 8 cycles of therapy (12 and 24 weeks after study entry) until disease progression/relapse, or death, whichever occurred first (overall up to approximately 2.75 years)

  3. Area Under the Plasma Concentration-Time Curve From Time 0 to Day 28 (AUC0-28) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  4. Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity AUC(0-inf) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  5. Percentage of Participants With Overall Response According to the International Workshop to Standardize Response Criteria for NHL

    Time frame: Day 1, after 4 and 8 cycles of therapy (12 and 24 weeks after study entry) until disease progression/relapse, or death, whichever occurred first (overall up to approximately 2.75 years)

  6. Maximum Plasma Concentration (Cmax) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  7. Systemic Clearance (CL) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  8. Steady State Volume of Distribution (Vss) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  9. Terminal Elimination Half-Life (t1/2) of Ocrelizumab

    Time frame: Pre-infusion (0-2 hours); 30 minutes post infusion on Day 1 of Cycles 1 to 8 (Cycle length = 21 days); Days 2, 8, and 15 of Cycle 1 (Cohorts A, B), Cycle 2 (Cohort C), and Cycle 8 (Cohorts A, B, C); Days 176, 190, 204, 259, 322, 357, 539

  10. Number of Participants With Peripheral Blood B-cell Depletion

    Time frame: Week 24, 28 days following the final infusion (Day 176), 9, 18, 24, and 30 months after study entry or until B cell recovery, whichever occurred first (up to approximately 2.75 years)

  11. Number of Participants With Peripheral Blood B-cell Recovery

    Time frame: Week 24, 28 days following the final infusion (Day 176), 9, 18, 24, and 30 months after study entry or until B cell recovery, whichever occurred first (up to approximately 2.75 years)

07

Study locations

23 sites
  • Melbourne, 3002, Australia
  • Perth, 6000, Australia
  • Woolloongabba, 4102, Australia
  • Edmonton, Alberta T6G 1Z2, Canada
  • Vancouver, British Columbia V5Z 4E6, Canada
  • Halifax, Nova Scotia B3H 2Y9, Canada
  • Ottawa, Ontario K1H 1C4, Canada
  • Toronto, Ontario M5G 2M9, Canada
  • Creteil, 94010, France
  • Lille, 59037, France
  • Nantes, 44093, France
  • Pierre Benite, 69495, France
  • Rennes, 35033, France
  • Bergamo, 24127, Italy
  • Roma, 00161, Italy
  • Torino, 10126, Italy
  • Huddinge, 14186, Sweden
  • Lund, 22185, Sweden
  • Malmoe, 20502, Sweden
  • Umea, 90185, Sweden
  • Bern, 3010, Switzerland
  • Geneve, 1211, Switzerland
  • Lugano, 6900, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2005, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2016
First posted
Mar 30, 2016
Start
May 2005
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Last update
Mar 30, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 30, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02723071
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 30, 2016
Start date
May 2005
Primary completion
Jan 2008
Completion
Jan 2008
Last update
Mar 30, 2016

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocrelizumab

Start the discussion